Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From diaDexus, Inc.
Public Company Edition: Moderna leveraged its all-time high stock price to raise $1.34bn on the same day it reported data from a Phase I trial of its COVID-19 vaccine. Several other companies also took advantage of biopharma’s rising value.
Commissioner Chopra says candy maker Nestlé cannot take Allergan’s place in the market and AstraZeneca would get a windfall without paying anything for a valuable drug development project. AbbVie/Allergan must divest enzyme replacement therapies Zenpap and Viokace to Nestlé and investigational IL-23 inhibitor brazikumab to AstraZeneca.
Another three in vitro diagnostics companies in Germany are working on tests for the early detection of COVID-19, with confirmed infections reaching 89,000 globally by 2 March.
Acquiring Encycle Therapeutics brings Zealand Pharma a promising IBD asset and expands the breadth of its peptide discovery platform.
- Other Names / Subsidiaries
- VaxGen, Inc.